当前位置:首页 - 行情中心 - 泰林生物(300813) - 财务分析 - 现金流量表

泰林生物

(300813)

  

流通市值:19.55亿  总市值:31.15亿
流通股本:7605.11万   总股本:1.21亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金78,884,224.82337,098,567.74235,266,522.34144,693,583.98
  收到的税费返还2,421,682.59,547,174.166,583,514.933,650,225.75
  收到其他与经营活动有关的现金7,469,390.529,117,118.5913,699,726.158,514,128.53
  经营活动现金流入小计88,775,297.84355,762,860.49255,549,763.42156,857,938.26
  购买商品、接受劳务支付的现金27,065,991.64111,933,636.0780,410,879.0645,460,508.04
  支付给职工以及为职工支付的现金47,095,100.53138,395,438.37106,489,360.3775,307,420.36
  支付的各项税费8,620,321.8623,584,464.0822,093,598.1913,306,346.33
  支付其他与经营活动有关的现金9,550,894.734,127,312.5331,696,769.8119,662,977.18
  经营活动现金流出小计92,332,308.73308,040,851.05240,690,607.43153,737,251.91
  经营活动产生的现金流量净额-3,557,010.8947,722,009.4414,859,155.993,120,686.35
二、投资活动产生的现金流量:
  收回投资收到的现金--586,145.83-
  取得投资收益收到的现金-9,384,212.49--
  收到的其他与投资活动有关的现金361,909,860.581,241,004,000762,697,678.17596,652,600.71
  投资活动现金流入小计361,909,860.581,250,388,212.49763,283,824596,652,600.71
  购建固定资产、无形资产和其他长期资产支付的现金8,774,544.546,885,597.3318,686,237.1217,581,203.12
  投资支付的现金-2,000,000--
  支付其他与投资活动有关的现金283,000,0001,199,100,000726,000,000552,900,000
  投资活动现金流出小计291,774,544.51,247,985,597.33744,686,237.12570,481,203.12
  投资活动产生的现金流量净额70,135,316.082,402,615.1618,597,586.8826,171,397.59
三、筹资活动产生的现金流量:
  吸收投资收到的现金---11,174,000
  收到其他与筹资活动有关的现金-11,174,00011,174,000-
  筹资活动现金流入平衡项目-000
  筹资活动现金流入小计-11,174,00011,174,00011,174,000
  偿还债务支付的现金-3,669,656.413,669,656.413,669,656.41
  分配股利、利润或偿付利息支付的现金-24,719,669.2224,213,792.1312,125,603.81
  其中:子公司支付给少数股东的股利、利润-479,825.42--
  支付其他与筹资活动有关的现金47,169.8123,509,544.3123,675,515.5623,673,896.31
  筹资活动现金流出小计47,169.8151,898,869.9451,558,964.139,469,156.53
  筹资活动产生的现金流量净额-47,169.81-40,724,869.94-40,384,964.1-28,295,156.53
四、汇率变动对现金及现金等价物的影响-422,963.92-732,533.59-375,657.52-96,942.58
五、现金及现金等价物净增加额66,108,171.468,667,221.07-7,303,878.75899,984.83
  加:期初现金及现金等价物余额78,545,303.5369,878,082.4669,878,082.4669,878,082.46
  期末现金及现金等价物余额144,653,474.9978,545,303.5362,574,203.7170,778,067.29
补充资料:
  净利润-16,286,074.7-13,342,711.07
  资产减值准备-3,963,381.82-27,112.65
  固定资产和投资性房地产折旧-15,919,807.65-2,090,608.33
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-15,919,807.65-2,090,608.33
  无形资产摊销-749,661.96-210,666.95
  长期待摊费用摊销-4,160,512.79-2,030,830.27
  固定资产报废损失-371,037.57-364,069.45
  公允价值变动损失--20,441.21--
  财务费用--2,274,959.57--2,136,093.16
  投资损失--4,358,519.68-5,502.22
  递延所得税--929,625.94--291,583.63
  其中:递延所得税资产减少--81,679--384.53
    递延所得税负债增加--847,946.94--291,199.1
  存货的减少-13,861,292.84-2,544,825.9
  经营性应收项目的减少--1,227,940.18--6,824,903.04
  经营性应付项目的增加--4,400,013.8--16,291,023.18
  其他-5,621,740.49--
  现金的期末余额-78,545,303.53-70,778,067.29
  减:现金的期初余额-69,878,082.46-69,878,082.46
  现金及现金等价物的净增加额-8,667,221.07-899,984.83
公告日期2026-04-302026-03-272025-10-272025-08-29
审计意见(境内)标准无保留意见
TOP↑